There's a Lot to Like in AbbVie's Q3 Update
AbbVie (NYSE: ABBV) has set a pattern in recent quarters of meeting or barely exceeding consensus analysts' earnings estimates. It's not that the big biotech hasn't performed well; rather, expectations have been pretty high for AbbVie.
That was the case once more for AbbVie entering the third quarter. The company announced its earnings results before the market opened on Friday. AbbVie yet again turned in a strong performance. And it yet again narrowly topped earnings estimates. Here are the highlights.
Source: Fool.com
AbbVie Inc. Stock
With 34 Buy predictions and not a single Sell prediction AbbVie Inc. is an absolute favorite of our community.
With a target price of 180 € there is a slightly positive potential of 3.65% for AbbVie Inc. compared to the current price of 173.66 €.